LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3046% below fair value
$4.13+0.04 (+0.98%)
Close on Nov 13, 2026Market cap $129.77MP/E –Yield –
LENZ Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 97.8%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 97.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 94.9% | – |
| Q1 FY2026 | Mar 31, 2026 | 43.4% | – |
| Q2 FY2025 | Jun 30, 2025 | 100.0% | – |
See a number that looks wrong?